Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 4, 2012

Cresset, Optibrium Swap Software to Improve Respective Drug Discovery Solutions

  • U.K.-based Cresset and Optibrium inked a collaboration through which each firm will provide the other with access to specific in silico drug discovery solutions. Under terms of the technology exchange agreement, users of Cresset’s desktop applications will have access to Optibrium’s ADME models solution, which is currently provided as a plug-in module for its StarDrop software platform. Cresset’s FieldAlign SAR software will in return be made available as an optional plug-in module to StarDrop. Optibrium claims use of the FieldAlign module will provide a 3-D view of compound interactions to complement the software’s existing 2-D QSAR models.

    Optibrium was established in 2009 as a spin-out from BioFocus DPI, to develop and commercialize the StarDrop software suite for use in drug candidate design, selection, and decision making. StarDrop integrates in silico and experimentally measured properties using a multiparameter optimization approach, chemical space, and Glowing Molecule™ visualizations and predictive modeling.

    Cresset’s Field technology is being exploited to provide insights into the biological activity, properties, and interactions of drug molecules. The firm has developed a range of solutions based on the platform, for applications in ligand-based virtual screening (FIeldScreen), bioisostere identification (FieldStere), bioactive conformation determination (FieldTemplater), as well as ligand alignment (FieldAlign). 

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »